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ABSTRACT 
Purpose of review: It is 20 years since the start of the combination antiretroviral therapy 
(cART) era and >10 years since cART scale-up began in resource-limited settings. We 
examined survival of vertically HIV-infected infants and children in the cART era. 
Recent findings: Good survival has been achieved on cART in all settings with up to ten-fold 
mortality reductions compared to before cART availability. Although mortality risk remains 
high in the first few months after cART initiation in young children with severe disease, it 
drops rapidly thereafter even for those who started with advanced disease, and longer term 
mortality risk is low. However, suboptimal retention on cART in routine programs threatens 
good survival outcomes and even on treatment children continue to experience high 
comorbidity risk; infections remain the major cause of death. Interventions to address 
infection risk include co-trimoxazole prophylaxis, isoniazid preventive therapy, routine 
childhood and influenza immunization and improving maternal survival. 
Summary:  
Pediatric survival has improved substantially with cART and HIV-infected children are aging 
into adulthood. It is important to ensure access to diagnosis and early cART, good program 
retention as well as optimal co-morbidity prophylaxis and treatment to achieve the best 
possible long-term survival and health outcomes for vertically infected children.  
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Abbreviations 
ADC AIDS-defining cancer 
ARROW Antiretroviral Research for Watoto 
cART combination antiretroviral therapy 
CHER Children with HIV Early antiRetroviral study 
CY child years 
DR-TB Drug resistant tuberculosis 
EID early infant diagnosis 
EPPICC European Pregnancy and Paediatric HIV Cohort Collaboration 
LTFU loss to follow-up 
PCV pneumococcal conjugate vaccine 
PMTCT prevention of mother to child transmission 
RCT randomized controlled trial 
RLS resource-limited settings 
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Introduction 
HIV-related paediatric deaths in 2014 were impressively nearly 50% fewer than in 2004, largely due 
to reductions in new pediatric infections (58% decrease since 2000) through prevention of mother to 
child transmission (PMTCT) programs [1,2,3]. Nevertheless, HIV remains a leading cause of child 
deaths, especially among those >5 years old where the burden of children infected before good 
coverage of effective PMTCT is substantial [4]. Globally, HIV is the twelfth leading cause of child 
deaths and among the top five leading causes in high prevalence countries [4]. Optimizing survival of 
the 2.6 million children living with HIV therefore remains important [3]. 
 
Survival of children in the absence of combination antiretroviral therapy  
In sub-Saharan Africa approximately half of perinatally infected and a quarter of infants infected 
through breastfeeding will die before their second birthday, compared to <5% infant mortality in 
HIV-exposed uninfected infants [5,6,7].Mortality in untreated perinatally infected infants was so 
high that in South Africa it caused an increase in all-cause mortality at 2-3 months of age from 1997-
2002 [8]. In the United States/Europe mortality in the absence of combination antiretroviral therapy 
(cART) was lower; 1-year mortality was 6.5-30% in 6-month-old infants [9,10]. 
Due to survivor bias, mortality without cART decreases markedly in children surviving to two years. 
The Joint United Nations Programme on HIV/AIDS (UNAIDS) Spectrum model estimates that survival 
probability to age 20 years without cART increases with timing of infection from 9% (infected at 
birth) to 24% (infected through breastfeeding), although data to inform assumptions for children 
aged >2.5 years is limited [11,12,13]. Annual mortality estimates without treatment in USA/Europe 
ranged from 1.2-12.0% in 2 year olds to 0.2–2.1% in children aged 10 years; CD4 was a poorer 
predictor of mortality in younger children [10]. In resource-limited settings (RLS), mortality is higher 
for equivalent age and CD4 values, and CD4 is less discriminatory for predicting mortality than in 
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well-resourced countries; annual risk varied by CD4% from 2.6-32.5% in 1-2 year olds to 0.6-23.0% in 
children ≥7 years (Figure 1) [10,14]. Viral load was a much weaker predictor of mortality than CD4 
count/percent [10]. 
 
Impact of cART on survival 
Developed country cohorts of mainly older children, initially demonstrated the survival benefit of 
cART [15]. Subsequently, studies have examined whether there is a survival benefit of immediate 
versus deferred therapy. The Children with HIV Early antiRetroviral (CHER) randomized controlled 
trial (RCT)showed 75% mortality reduction by 40 weeks in infants aged <3 months who started 
immediate early limited cART (until first or second birthday) compared to deferring until 
immunologic or clinical progression (defined as WHO 2006 cART initiation thresholds) [16]. However, 
a smaller RCT showed no mortality benefit of immediate cART at CD4 15-24% versus deferring until a 
CDC Stage C event or CD4 <15% in older Thai children (median age 6.4 years) [17]. Notably, the 
overall event rate was low and few children were in the younger age groups where the benefit of 
immediate cART is likely to be highest [17]. Causal modelling analyses that adjust for time-
dependent confounding affected by prior treatment showed no mortality benefit of immediate cART 
in 1-5 year old children, possibly because few children in routine care presented with  
CD4 count >750 cells/µl or CD4% >25% (WHO 2010 cART initiation threshold) and a high proportion 
was lost to follow-up (LTFU) with likely mortality under-ascertainment [18,19]. For children 5-10 
years old, causal modelling showed a small but significant mortality benefit of 0.4% (95% Confidence 
IntervaI [CI]: 0.02-0.6%) by 5 years of follow-up when starting cART immediately versus deferring 
until CD4 <500 cells/µl (Figure 2) [20]. 
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Survival on cART in routine care 
Middle and high income countries: Long-term cohorts from USA and Europe report a ten-fold 
mortality rate decline over calendar years (7.2-8.2/100 child years (CY) in the late 1990s vs 0.6-
0.8/100 CY in 2000-2006), with plateauing thereafter [21,22]. In these cohorts, 72-83% of children 
received cART [21,22] and 6-10 year survival probabilities during the cART era were >94-98% 
[22,23,24]. The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) reported 
nearly ten-fold higher mortality in the first 6 months on cART (2.5/100 CY vs 0.27/100 CY) compared 
to later. After the first 6 months on cART, children <2 years old and adolescents ≥14 years had higher 
mortality versus 5-<14 year olds (aHR [95%CI] <2 years: 3.7 [1.2-10.8]; >14 years: 1.8 [0.9-3.7]). 
Mortality was 50% lower in high versus middle income (Thailand and Eastern Europe) countries [25]. 
Mortality was only 5% by nearly 6 years median follow-up in an EPPICC study of infants starting cART 
(median age <4 months) [26]. Despite overwhelming cART success, mortality remains nearly 30 
times higher than in the general population [22].  
Resource limited settings: There are >80 publications of survival on cART from a range of RLS 
[27,28,29,30,31,32], including trials, cohorts and national programs, with increasing follow-up 
durations. Clinical trials with high retention and adherence demonstrate good survival on cART, 
especially after the first 6 months, even in peripheral clinics [16,33,34,35,36]. In the Antiretroviral 
Research for Watoto (ARROW) RCT of different monitoring strategies, one-year mortality on cART 
ranged from 1.3%-10.1% in children aged 4-15 years with CD4 ≥100 and <50 cells/µl respectively 
[36]. Corresponding values for children 4 months to 3 years were 9.1% (CD4% <5%) and 2.8% (CD4% 
>10%) (Figure 3) [36]. Although mortality was high in the first 3 month of cART, it declined rapidly to 
<5% by one year for all age and CD4 strata [36]. The third Children with HIV in Africa – 
Pharmacokinetics and Adherence of Simple ARV Regimens trial (CHAPAS 3) of different 
nonnucleoside reverse transcriptase inhibitor-based first-line cART regimens reported similar low 
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mortality of 4.0% by 2.3 years median follow-up [35]. In CHER, mortality was 9% by median follow-
up of 4.8 years in infants initiating immediate cART at <3 months old [33].  
Routine cART programmes in RLS suggest poorer and more variable survival than trials, partly due to 
lower retention and programmatic or adherence-related challenges, including drug stockouts. 
Indeed, better survival in children with greater adherence to placebo in a co-trimoxazole prophylaxis 
trial suggests that good adherence may be a surrogate for overall better child care [37]. Mortality by 
2 years or more on cART from routine programs in RLS ranges from 3.7 to 29% [38,39] and rates vary 
from 1.3-6.0/100 CY [40,41]. Children still initiate treatment with severe disease with mortality 
remaining higher in the first year (Figure 3)[42]. Young age and severe disease are consistently 
associated with higher mortality [28,31,43,44,45,46]. Prognostic models for RLS predict one-year 
mortality on cART ranging from <2% (children 5-10 years, no severe disease, CD4%>10%) to >45% 
(infants, severe disease, CD4<5%)[47,48]. Nevertheless, nearly 60% of children in the prognostic 
model study cohort had characteristics predicting low (<5%) 1-year mortality [47]. 
Importantly, there are concerns about survival on cART and interpreting outcomes of routine 
programs in RLS. First, routine cohorts frequently report high LTFU (>10%) with likely unascertained 
mortality [38,49,50,51]. In Malawi, mortality was 11% among children traced from three weeks after 
a missed visit [52]; using longer durations to define LTFU, mortality was nearly 40%among LTFU [38]. 
Second, many programs have high transfer rates, particularly in recent years with decentralisation of 
cART programmes [23,28,31,53,54,55,56,57,58]. While decentralization may contribute to better 
retention [54,59], limited ability to track outcomes after transfer hampers long-term survival 
assessment. Additionally, unrecorded transfers to another facility add to high LTFU rates with 
underestimation of survival at the program level [52]. Third, some programs report worsening 
outcomes [39,45,54]; from 2005-2008 in Cote d’Ivoire, one-year mortality and LTFU increased from 
3% to 11% and 2% to 23% respectively [45]. In rural Mozambique mortality and LTFU were 16-24% 
and 25-70% respectively with substantial heterogeneity between districts [39]. Finally, infants 
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remain vulnerable with poor outcomes in routine care in RLS despite WHO recommendations for 
universal cART since 2010 [60]. Although more infants have initiated cART with less severe disease 
[61,62,63], a substantial proportion still start treatment late [64,65]. In Southern Africa, despite 
significant improvements after 2010, one-year mortality (13%) and LTFU (19%)remained high overall 
[61]. While annual mortality on cART was lower in Botswana (4.6/100CY), only 60% of infants 
initiated treatment [56]; 39% of all HIV-infected infants died [56]. 
Infant survival requires early infant diagnosis (EID) with rapid cART initiation. In 2014, only 50% of 
HIV-exposed infants were tested by age 2 months; only a third of those diagnosed started cART 
promptly [66,67,68]. At best, most infants initiate treatment between 12-14 weeks, after the infant 
mortality peak [8,69]. Innovative approaches (point-of-care assays; adding birth EID) may accelerate 
diagnosis and cART initiation; but further implementation research is needed [69,70,71,72,73].  
With increasing coverage of PMTCT, most new pediatric infections are in infants whose mothers did 
not access PMTCT; hence not identified through post-PMTCT EID programs. Identifying children 
missed by EID is critical, and remains challenging [74]. The proportion of children newly diagnosed 
through provider-initiated testing in hospitals or malnutrition centres is high (6%-22%). Testing 
strategies outside PMTCT programmes need to be strongly emphasized 
[72,75,76,77,78,79,80,81,82]. 
 
Models of care to optimize real world survival on cART 
Given WHO 2015 recommendations to start everyone on cART [83] and UNAIDS targets (90% of HIV-
infected people are diagnosed, 90% retained on cART, with 90% virologic suppression [84]), focus is 
shifting from “when to start” to achieving optimal treatment access and outcomes. Encouragingly, 
decentralization of pediatric HIV care has increased with good outcomes [85]. Survival and retention 
may be better for children treated nearer their homes, especially with community support 
 9 
 
[38,41,50,86]. Facilities with better quality of care [29]and high health worker morale report better 
outcomes, particularly lower LTFU [45]. Good outcomes in Rwanda (≤5% one-year LTFU or mortality) 
were ascribed to staff mentoring and decentralization [59]. 
Comorbidities that reduce survival in HIV-infected children 
Even with cART, comorbidity incidence (including tuberculosis, childhood infections and 
malignancies) is higher in HIV-infected than uninfected children [87,88,89,90,91]; infections still 
predominate as causes of death [21,22,92,93]. AIDS-defining infections have declined, but non-AIDS 
defining conditions (sepsis; pneumonia) remain relatively stable [21,22,92,93,94]. The contribution 
of non-infectious conditions (metabolic syndrome, renal, liver and cardiovascular disease) in children 
is not clear. 
Tuberculosis: In 2015, global estimates showed that up to 30% of HIV-infected child deaths may be 
tuberculosis-related [95]. HIV-infected children are more than twice as likely to die from tuberculosis 
compared to HIV-uninfected children [96,97,98]; within pediatric HIV cohorts tuberculosis increases 
mortality risk 2-4 times [99,100]. Infants are at the highest risk with nearly 30% mortality with 
bacteriologically confirmed tuberculosis [101]. While cART reduces tuberculosis-related mortality 
substantially [99,102], delays in cART initiation remain challenging [100,103]. Unlike in adults 
[104,105], there are no RCTs on the optimal timing of cART initiation in tuberculosis co-infected 
children. Observational studies showed better survival with starting cART within 2 months (or less) 
of tuberculosis therapy compared to later [106,107,108], but it is unclear whether early cART 
improves survival in co-infected children without severe immunocompromise. 
Treatment outcomes for children with drug resistant tuberculosis (DR-TB) vary widely. A South 
African study of DR-TB (55% of children HIV-infected) found 20% overall mortality [109], while a 
systematic review found mortality was twice as high in HIV-infected compared to uninfected 
children (11.5% vs. 6%) [110]. 
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Malignancy: Cancer is ≥5-10 times more common in HIV-infected compared to uninfected children 
[87,91,111,112,113]. In the cART era, AIDS-defining cancers (ADCs) have reduced dramatically, but 
non-ADC rates remain unchanged or increased [87,91,114]. Treatment outcomes are worse in HIV-
infected vs HIV-uninfected children [111]. In South Africa >80% of HIV-infected children with cancer 
presented with advanced disease; only a third survived. Survival was higher (57.8%) if treated with 
cART and chemotherapy [115]. In Uganda, half of HIV-infected children with cancer died or were 
LTFU; mortality was at least three-fold higher than the clinic crude mortality rate (33% vs 5-10%) 
[116].The increasing rates of some non-ADCs in the cART era is likely due to increased life 
expectancy allowing development of these cancers, however the impact of long-term cART has been 
debated. With vertically infected children surviving into adulthood there is growing concern about 
malignancy risk and associated mortality. 
 
Interventions other than ART to improve survival in HIV-infected children 
Co-trimoxazole  
Use of cotrimoxazole nearly  halved all-cause mortality in cART-naïve Zambian children despite high 
levels of bacterial resistance [117,118]. The ARROW trial found fewer hospitalizations when 
continuing co-trimoxazole in Ugandan/Zimbabwean children after 2 years of cART, hence WHO 
recommends continuing prophylaxis until adulthood if prevalence of bacterial infections and malaria 
is high [119,120].Co-trimoxazole appears protective against incident tuberculosis in HIV-infected 
adults and possibly children[89,121] and reduces mortality and morbidity in people with 
HIV/tuberculosis [122,123].Adding co-trimoxazole to anti-tuberculosis treatment has been 
successfully implemented in high tuberculosis burden countries with 87% coverage in co-infected 
patients [95]. 
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Evidence of survival benefit of isoniazid preventive treatment (IPT) in HIV-infected children is 
conflicting. IPT halved all-cause mortality in an RCT including mostly cART-naïve children [124]; a 
subsequent cohort study demonstrated additional benefit of IPT on tuberculosis incidence in 
children on cART [125]. Contrastingly, an RCT in infants showed no mortality or tuberculosis 
prevention benefit of pre-exposure IPT [126], however infants were screened for tuberculosis 
exposure at every visit, with prompt post-exposure IPT. While this approach is unlikely to be feasible 
in routine care where uptake of post-exposure IPT has been shown to be very low [127,128], pre-
exposure IPT for children in HIV clinics can have high uptake and treatment completion [129]. 
Although WHO has recommended pre-exposure IPT since 2004, coverage remains disappointingly 
low [95]. Barriers to IPT implementation include exaggerated fear of resistance development [130], 
unavailability of single entity isoniazid formulations in RLS and concerns about increased pill burden 
affecting cART adherence [131]. A scored fixed dose combination of isoniazid, vitamin B6 and co-
trimoxazole was highly acceptable to adults and children >5 years  in the Reduction of EArly 
mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy  trial [132] and could 
help overcome universal IPT implementation barriers; a half-strength scored dispersible tablet is 
needed for younger children. 
Routine immunization 
Since common childhood infections remain the leading causes of death in HIV-infected children, 
routine childhood immunisations may improve survival [94]. Haemophilus influenza, pneumococcal 
conjugate vaccines (PCV) and seasonal influenza vaccinations prevent severe infections in HIV-
infected children [88,133]. Influenza and PCV may reduce tuberculosis-related mortality as influenza 
epidemics lead to increased hospitalizations for invasive pneumococcal disease and pulmonary 
tuberculosis [88]. Further, PCV appeared protective against tuberculosis[134]. The high prevalence 
of rotavirus gastroenteritis in HIV-infected infants in RLS indicates a potential survival benefit of 
vaccination [135,136]. Rotavirus vaccine efficacy is lower in high-mortality countries but disease 
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burden is higher, hence the absolute benefit is large [137]. A package of preventive strategies 
addressing common co-morbidities should be considered to optimize survival. 
Maternal health, socio-economic status and treatment of OI in adults 
Several studies show links between maternal and infant survival - maternal HIV/AIDS or tuberculosis-
related death reduce child survival [138,139,140]. Maternal cART protected against under-five 
mortality; death rates in children of HIV-infected mothers were reduced to levels of children of HIV-
uninfected mothers [141]. Maternal health is therefore important and “Option B+” (lifelong cART for 
pregnant/breastfeeding women) offers key child survival benefit. 
 
Conclusion 
Pediatric survival has improved substantially with cART; with the additional success of PMTCT 
programs in preventing new infant infections, focus can start to shift from averting deaths to 
optimizing health for adolescence and adulthood. Nevertheless, there remain substantial survival 
gains to be made especially in RLS by strengthening health systems and improving models of 
decentralised HIV care to ensure access to diagnosis and early cART at all levels of the health system, 
continuous drug supplies, better adherence and retention, prophylaxis and treatment for co-
morbidities, as well as promoting maternal survival including maternal cART. 
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Key points 
 Good survival has been achieved during the cART era in all settings with up to ten-fold 
mortality reductions compared to before cART availability.  
 Immediate cART has been shown to improve survival compared to deferring until clinical or 
immunological progression in infants in the CHER RCT, and in children aged 5-10 years in 
causal modelling analyses of cohort data. 
 Since mortality risk remains high in the first few months after cART initiation in young 
children with severe disease, it is important to improve access to early diagnosis and cART 
before disease progression; nevertheless mortality drops rapidly after the first 6 months on 
cART even for those who started with advanced disease, and longer term mortality risk is 
low in all settings 
 Routine programs providing pediatric cART in resource-limited settings frequently report 
high loss to follow-up which may include unascertained mortality and suboptimal retention 
on cART threatens potential good survival outcomes. 
 HIV-infected children continue to experience high comorbidity risk even when treated with 
cART with infections remaining the major cause of death; interventions shown to reduce 
infection risk and related mortality include co-trimoxazole prophylaxis, isoniazid preventive 
therapy, routine childhood and influenza immunization and improving maternal survival. 
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Figures: 
Figure 1. Estimated risk of death within 12-months in Cross Continents Collaboration for Kids 
(3Cs4kids) (low and middle-income countries) compared with HIV Paediatric Prognostic 
Collaborative Study (HPPMCS)(USA and Europe) according to age and: (a) CD4% (b) CD4 cell count. 
Estimates in 3Cs4kids apply to a child receiving co-trimoxazole prophylaxis. Curves are truncated at 
the 5th and 95th centiles for each age. Source: Cross Continents Collaboration for Kids (3Cs4kids) 
Analysis and Writing Committee. Markers for predicting mortality in untreated HIV-infected children 
in resource-limited settings: a meta-analysis. AIDS. 2008; 22:97-105. 
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Figure 2. Estimated mortality from enrolment into HIV care in children aged 5-10 years at enrolment 
with initial CD4 >500 cells/µl from Southern Africa, West Africa and Europe comparing different cART 
initiation strategies as follows: immediate cART; cART at CD4 < 500 or weight-for-age z-score 
(WAZ)<-2; CD4 <350/WAZ <-2; CD4 <200/WAZ <-2; no cART. The mortality difference between 
immediate cART (solid green line) and deferring cART to CD4 >500 cells/µl or WAZ<-2 is 0.4% (95%CI: 
0.02-0.6%). Mortality is estimated from g-computation to adjust for time-dependent confounding 
affected by prior treatment of CD4 count, CD4 percent and weight-for-age z-score. 
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Figure 3. Daily risk of death through 1 year on cART in children aged 4 months to 15 years in the 
ARROW RCT according to age and pre-cART CD4 count or percent using flexible parametric models 
on log-normal scale with 1 interior knot. Points show times when deaths occurred. Source: Walker 
AS, et al. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and 
children in Uganda and Zimbabwe. Clinical Infectious Diseases. 2012; 55:1707-18.  
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